- Home
- SUGP vs KAPA Comparison
SUGP vs KAPA Comparison
Compare SUGP & KAPA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUGP
- KAPA
- Stock Information
- Founded
- SUGP 1998
- KAPA 2013
- Country
- SUGP Hong Kong
- KAPA United States
- Employees
- SUGP N/A
- KAPA N/A
- Industry
- SUGP
- KAPA
- Sector
- SUGP
- KAPA
- Exchange
- SUGP NYSE
- KAPA NYSE
- Market Cap
- SUGP 9.6M
- KAPA 10.8M
- IPO Year
- SUGP 2024
- KAPA 2024
- Fundamental
- Price
- SUGP $0.46
- KAPA $0.65
- Analyst Decision
- SUGP
- KAPA Strong Buy
- Analyst Count
- SUGP 0
- KAPA 3
- Target Price
- SUGP N/A
- KAPA $8.33
- AVG Volume (30 Days)
- SUGP 151.7K
- KAPA 1.5M
- Earning Date
- SUGP 07-21-2025
- KAPA 08-23-2025
- Dividend Yield
- SUGP N/A
- KAPA N/A
- EPS Growth
- SUGP N/A
- KAPA N/A
- EPS
- SUGP N/A
- KAPA N/A
- Revenue
- SUGP $25,478,980.00
- KAPA N/A
- Revenue This Year
- SUGP N/A
- KAPA N/A
- Revenue Next Year
- SUGP N/A
- KAPA N/A
- P/E Ratio
- SUGP N/A
- KAPA N/A
- Revenue Growth
- SUGP 25.07
- KAPA N/A
- 52 Week Low
- SUGP $0.35
- KAPA $0.40
- 52 Week High
- SUGP $3.25
- KAPA $4.00
- Technical
- Relative Strength Index (RSI)
- SUGP 33.09
- KAPA N/A
- Support Level
- SUGP $0.43
- KAPA N/A
- Resistance Level
- SUGP $0.52
- KAPA N/A
- Average True Range (ATR)
- SUGP 0.07
- KAPA 0.00
- MACD
- SUGP -0.00
- KAPA 0.00
- Stochastic Oscillator
- SUGP 34.63
- KAPA 0.00
About SUGP SU GROUP HLDGS LTD
SU Group Holdings Ltd and its subsidiaries is an integrated security-related services company. The company has two reportable segments: security-related engineering services, and security guarding and screening services and related vocational training services. The company generates the majority of its revenue from the security-related engineering services segment. Geographically operates in Hong Kong, and Other foreign countries, with maximum revenue from Kong Kong.
About KAPA KAIROS PHARMA LTD
Kairos Pharma Ltd is a clinical-stage biopharmaceutical company. It is engaged in therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma.